BRAF-FAM131B (Fex2Bex9)

FAM131B-BRAF · Variant type: fusion · Fusion partner: FAM131B (Fex2Bex9)

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Ripretinib	99.4%	0.6%	92.95
2	Regorafenib	99.4%	0.6%	95.99
3	Sorafenib	99.2%	0.8%	96.72
4	Encorafenib	99.1%	0.9%	98.50
5	Dabrafenib	98.9%	1.1%	94.74
6	Ponatinib	98.8%	1.2%	78.23
7	Vemurafenib	98.3%	1.7%	96.49
8	Apatinib	93.4%	6.6%	97.73
9	Nilotinib	91.8%	8.2%	96.49
10	Dasatinib	88.2%	11.8%	87.97
11	Pazopanib	77.8%	22.2%	97.49
12	Erdafitinib	77.2%	22.8%	95.71
13	Umbralisib	61.3%	38.7%	98.74
14	Rabusertib	58.3%	41.7%	98.74
15	Gedatolisib	55.0%	45.0%	99.75
16	Pacritinib	50.1%	49.9%	88.64
17	Imatinib	47.0%	53.0%	99.00
18	Upadacitinib	46.6%	53.4%	97.98
19	Tivozanib	39.2%	60.8%	92.42
20	Dacomitinib	38.9%	61.1%	97.99
21	Ibrutinib	36.3%	63.7%	94.74
22	Canertinib	35.4%	64.6%	96.49
23	Osimertinib	29.5%	70.5%	97.24
24	Afatinib	26.2%	73.8%	98.50
25	Vandetanib	23.5%	76.5%	95.74

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Ripretinib	99.4%	—	—
Regorafenib	99.4%	—	—
Sorafenib	99.2%	—	—
Encorafenib	99.1%	—	—
Dabrafenib	98.9%	—	—
Ponatinib	98.8%	—	—
Vemurafenib	98.3%	—	—
Apatinib	93.4%	—	—
Nilotinib	91.8%	—	—
Dasatinib	88.2%	—	—
Pazopanib	77.8%	—	—
Erdafitinib	77.2%	—	—
Umbralisib	61.3%	—	—
Rabusertib	58.3%	—	—
Gedatolisib	55.0%	—	—
Pacritinib	50.1%	—	—
Imatinib	47.0%	—	—
Upadacitinib	46.6%	—	—
Tivozanib	39.2%	—	—
Dacomitinib	38.9%	—	—
Ibrutinib	36.3%	—	—
Canertinib	35.4%	—	—
Osimertinib	29.5%	—	—
Afatinib	26.2%	—	—
Vandetanib	23.5%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 13.2ms